Assignee
ARROWHEAD PHARMACEUTICALS INC
US·76 granted patents·81 pending applications·153 citations·filing 2016–2025
Top patents by PatentIndex Score
157 records- 0196US10450565B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 22, 2019·15 cites·39 claims
- 0296US10130651B2RNAi Therapy for Hepatitis B Virus InfectionARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Nov 20, 2018·22 cites·18 claims
- 0395US11884920B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Jan 30, 2024·2 cites·21 claims
- 0495US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
- 0594US12188017B2Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 7, 2025·1 cites·12 claims
- 0694US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 0794US11214801B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·3 cites·30 claims
- 0893US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
- 0993US10597657B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·6 cites·51 claims
- 1092US11629349B2RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Apr 18, 2023·3 cites·14 claims
- 1192US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 1292US11549112B1RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 10, 2023·3 cites·14 claims
- 1392US11203756B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Dec 21, 2021·5 cites·25 claims
- 1492US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 1592US10294474B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted May 21, 2019·15 cites·50 claims
- 1692US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
- 1791US11384355B2Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Jul 12, 2022·3 cites·23 claims
- 1890US10240153B2Organic compositions to treat APOC3-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Mar 26, 2019·7 cites·17 claims
- 1990US2025197861A1Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2089US11174481B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 16, 2021·3 cites·4 claims
- 2189USRE48345ECompositions and methods for inhibiting gene expression of hepatitis B virusARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Dec 8, 2020·3 cites·69 claims
- 2289US10806750B2RNAi therapy for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·3 cites·9 claims
- 2387US10308941B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·4 cites·26 claims
- 2487US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2586US11845937B2RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Dec 19, 2023·1 cites·22 claims
- 2686US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
- 2786US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 2886US10287582B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted May 14, 2019·3 cites·18 claims
- 2986US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3085US12365899B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·22 claims
- 3185US2026043025A1RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3285US2022364097A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3384US2024141351A1Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3483US12091661B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Sep 17, 2024·0 cites·20 claims
- 3583US10995335B2RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 4, 2021·3 cites·19 claims
- 3683US2025270555A1Organic compositions to treat beta-catenin-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3783US2022162614A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3882US11597701B2Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·2 cites·24 claims
- 3982US2022235361A1RNAi Inhibition of Alpha-ENaC ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4082US2022042021A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4181US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
- 4281US10544418B2RNAi inhibition of alpha-ENaC expressionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Jan 28, 2020·1 cites·13 claims
- 4381US2022112505A1RNAi Inhibition of Alpha-ENaC ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4480US12110492B2RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Oct 8, 2024·0 cites·14 claims
- 4580US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4679US12378558B2RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2024·Granted Aug 5, 2025·0 cites·19 claims
- 4779US2021230603A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4879US2023355654A1Rnai therapy for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4979US2021108206A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 5078US9752152B2Organic compositions to treat beta-ENaC-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 5, 2017·1 cites·15 claims
Showing the top 50 of 157 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →